Development of nano-formulation containing crocetin for the protective and beneficial effect against 6-hydroxydopamine induced Parkinson’s disease model via altered the genetic backgrounds
Objective: Parkinson’s disease (PD) induced by the interaction between the number of factors viz., aging, genetics toxins, mitochondrial deformity and oxidative stress. Various evidences suggest…Effects of different intensity exercises on motor function of PD rats as well as the regulation of DA
Objective: This paper research the intervention effect of the different intensity treadmill exercise on motor function of Parkinson 's diseases (PD) model rats，and explore the…Non-motor symptoms in ACDY5-associated disease
Objective: To describe non-motor symptoms in a case of ACDY5-associated disease. Background: The hereditary dyskinesia syndrome caused by an ACDY5 mutation was first described in…Co-speech gestures in Parkinson’s disease (PD)
Objective: We develop an analytical description of co-speech gesture production in PD patients. Background: Communication and expressive behavior problems are frequent in PD patients (Duncan…VIT-D and Tics Movement Disorder
Objective: Tics is common childhood movement disorder, with classified variants , typically begin at around 4-5 years of age but often present lator at about…Noladin ether attenuates MPTP -induced motor deficit by abrogating pro-inflammatory cytokines and striatal neurochemical alterations in rats
Objective: The present study was designed to investigate the therapeutic potential of noladin ether- a putative endocannabinoid against MPTP-induced behavioral, biochemical and neurochemical alterations in…Impulsive-compulsive behaviors in patients with Parkinson’s disease and demographically-comparable group of healthy controls
Objective: To assess patients with Parkinson's disease (PwPD) impulsive-compulsive behaviors (ICBs) prevalence compared to healthy controls (HCs) group, to analyze PD clinical features, ICBs risk…Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia
Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…Disrupted motor memory in Parkinson’s disease
Objective: We sought to investigate the differences in motor adaptation and motor memory between people with Parkinson's disease (PD) and healthy age-matched controls by using…Curcumin supplementation improves motor dysfunction in lipopolysaccharide induced Parkinon’s disease model: Possible biochemical, neurochemical and immunohistochemical alterations in rats
Objective: In the present study potential neuroprotective effects of curcumin were tested to determine if they could help to minimize microglia–mediated damage in single intranigral…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- Next Page »